Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
NCT05178810 is registered in ClinicalTrials.gov with Ferrer Internacional S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
- Lead sponsor
- Ferrer Internacional S.A.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 18, 2021
- Completion date
- October 26, 2023
- Enrollment
- 313 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.